Last week New Mexico’s advisory board for the state’s medical marijuana program unanimously voted to add Alzheimer’s disease to the list of qualifying conditions for treatment by medical cannabis.  

If approved by the state’s Secretary of Health, New Mexico will become the 14th state to permit medical marijuana for treating Alzheimer’s.

New Mexico’s Drug Policy Alliance filed the petition to add neurodegenerative dementia to New Mexico’s Compassionate Use Act on behalf of the state’s Alzheimer’s patients.

Research on cannabis as a treatment for Alzheimer’s has been positive, including studies that found approved prescription drugs consistently failed to reduce Alzheimer’s-related brain inflammation, while cannabis was demonstrated to be the most effective anti-inflammatory medication when tested on animals.

New Mexico’s medical pot program currently has 16 qualifying conditions, including cancer, Crohn’s disease and anorexia.

Over 30,000 New Mexicans are living with Alzheimer’s disease – a figure projected to increase to more than 40,000 by 2025.